No need for dexamethasone for endophthalmitis treatment

Article

The use of intravitreal dexamethasone (IVD) is not warranted as a routine adjunctive treatment in postoperative endophthalmitis.

The use of intravitreal dexamethasone (IVD) is not warranted as a routine adjunctive treatment in postoperative endophthalmitis, according to a study published online ahead of print by Clinical Ophthalmology.

Edward Hall and colleagues from the University of Michigan, USA conducted a retrospective, comparative case series to evaluate the effect of adjunctive IVD use on visual outcomes in patients with acute endophthalmitis following cataract surgery. The study included 26 patients treated with adjunctive IVD and 38 without, between 1995 and 2004.

Median presenting visual acuity (VA) was hand motion in both groups. Median VA at last follow-up was 20/40 in the IVD group and 20/50 in the non-IVD group (p=0.75). Seventy-three percent of patients in the IVD groups and 82% in the non-IVD group achieved a ≥3 line improvement in VA (p=0.42). No significant difference was recorded between the two groups in cell count and flare, height of hypopyon or presence of fibrin as a function of time after treatment.

The use of IVD does not significantly improve final median VA or the amount of intraocular inflammation and thus, according to the authors, is not warranted as a routine adjunctive treatment in postoperative endophthalmitis.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.